StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Equities research analysts at StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

Shares of NASDAQ APVO opened at $0.34 on Friday. The business has a 50-day moving average of $1.37 and a 200-day moving average of $75.96. Aptevo Therapeutics has a 12 month low of $0.34 and a 12 month high of $33.67.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.